<DOC>
	<DOC>NCT02404675</DOC>
	<brief_summary>This randomized, open-label study is aimed to evaluate the efficacy of high-dose icotinib in treating advanced non-small cell lung cancer patients with positive EGFR 21 exon mutation.</brief_summary>
	<brief_title>High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>Histologically or cytologically confirmed stage IIIB/IV lung cancer(exclude patients confirmed by sputum cytology) Positive EGFR 21 exon mutation or 19 exon deletion Age 1875 years old with performance status of 0 to 2 With a measurable disease(longest diameters &gt;=10mm with Spiral computed tomography (CT)and &gt;=20mm with conventional CT) according to RECIST Criteria Adequate hematological, biochemical and organ functions. Severe systemic disease out of control such as unstable or uncompensated respiratory,cardiac,liver,renal diseases. Evidence of interstitial lung diseases Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>